Clinical Trial Update: A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated SB-742457 added to donepezil for mild-to-moderate Alzheimer's disease. The study is completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Aricept (Donepezil)
• SB-742457

Snippet

Sponsor: GlaxoSmithKline | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2017-12-07